June 18th 2025
The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.
Low-Fat Fish Oil Diet May Alter Prostate Tumor Biology
January 1st 2014Men with early-stage prostate cancer who ate a low-fat diet supplemented with fish oil had lower amounts of pro-inflammation molecules in their blood and lower prostate tumor cell proliferation compared with men who ate a high-fat Western diet.
Inflammation in Prostate Biopsy May Predict Lower Cancer Risk
December 27th 2013Markers of inflammation should be analyzed and reported in prostate biopsies, according to the results of a new study. Researchers found that negative prostate biopsies that had markers of inflammation were less likely to be diagnosed with prostate cancer in a subsequent prostate biopsy.
No Significant PFS Benefit With Axitinib in First-Line Metastatic RCC
November 19th 2013The second generation VEGFR inhibitor axitinib did not significantly improve progression-free survival in first-line treatment of patients with metastatic renal cell carcinoma compared with patients treated with sorafenib.
The Success of Therapies for Metastatic CRPC Continues
November 15th 2013I have read multiple overviews of the current management of castration-resistant prostate cancer (CRPC). These articles have very adeptly summarized the key trials leading to a multitude of US Food and Drug Administration (FDA) approvals of new agents for men with CRPC.
Sequencing Medical Therapy in Prostate Cancer: Not as Easy as 1-2-3
November 15th 2013With the emergence of several new agents for the treatment of advanced prostate cancer, new questions have arisen regarding the optimal sequence or combination of these agents. As we await the results of ongoing and planned clinical trials to answer some of these questions directly, the decision-making process will rely heavily on considerations of side effects and patient characteristics.
PFS May Be Valid Surrogate Endpoint for Overall Survival in Metastatic RCC
October 18th 2013Results of a recent study indicate that patient progression-free survival at 3 months and 6 months was predictive of the overall survival among metastatic RCC patients treated with interferon alpha and bevacizumab.
PSA Screening: Good Evidence Shows Little Benefit, Significant Harms
October 15th 2013The Task Force’s recommendation against PSA screening for prostate cancer is based on the best available science and the knowledge that, while we all want to prevent suffering and death from prostate cancer, PSA screening simply does not get us there.
PSA Screening in Men Newly Diagnosed With Colorectal Cancer: Each According to His Group’s Means?
October 15th 2013Once a patient has been appropriately educated by an informed healthcare provider about the possible benefits of PSA screening, then patient preference as part of shared decision making regarding PSA screening should be considered in all cases.
PSA Screening for Colorectal Cancer Patients: Proceeding With Caution
October 15th 2013It may be appropriate to offer prostate cancer screening to carefully selected men with a previous history of colorectal cancer. However, the risks and benefits of establishing the diagnosis in this setting need to be considered and discussed with them.
Should All Colorectal Cancer Patients Over Age 60 Be Screened for Prostate Cancer?
October 15th 2013Not all patients with colorectal cancer are candidates for such screening, however, as a remaining life expectancy of at least 10 years is generally required in order for PSA screening to yield a significant mortality benefit.
No Survival Benefit With Ipilimumab in Advanced Prostate Cancer
September 20th 2013In a phase III trial, ipilimumab increased the overall survival of men with advanced castration-resistant prostate cancer when used with a single dose of radiotherapy by 1.2 months, but the results were not statistically significant.